B · Normal
[Aidi Pharmaceutical: Plans to raise no more than 945 million yuan in additional funds for global clinical development projects of new HIV integrase inhibitors, etc.] On September 17, Aidi Pharmaceutical (688488.SH) announced that the company’s board of directors has reviewed and approved the plan to issue A shares to specific targets in 2026, with a total planned capital raising of no more than 945 million yuan, which will be used for global clinical development projects of new HIV integrase inhibitors, annual production of 500 million tablets of anti-AIDS solid preparation drugs, and supplementary working capital.
Comments